Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.

• Príomhchruthaitheoirí: Rinez Thapa (Údar), Subhasish Mondal (Údar), Joakim Riikonen (Údar), Jimi Rantanen (Údar), Simo Näkki (Údar), Tuomo Nissinen (Údar), Ale Närvänen (Údar), Vesa-Pekka Lehto (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Public Library of Science (PLoS), 2021-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Visceral leishmaniasis is a vector-borne protozoan infection that is fatal if untreated. There is no vaccination against the disease, and the current chemotherapeutic agents are ineffective due to increased resistance and severe side effects. Buparvaquone is a potential drug against the leishmaniase...